Vedanta Biosciences

Vedanta Biosciences is a late clinical-stage biopharmaceutical company headquartered at 19 Blackstone Street in Cambridge, Massachusetts, founded by PureTech Health together with a group of scientific co-founders who pioneered the modern understanding of cross-talk between the human microbiome and the immune system. The company develops a potential new category of oral Live Biotherapeutic Products built from rationally defined consortia of human commensal bacteria grown from pure clonal cell banks rather than donor-derived stool, and it maintains technical expertise in the manufacture of live organisms. Its lead program, VE303, is an eight-strain defined bacterial consortium in the global Phase 3 RESTORATiVE303 registrational study for the prevention of recurrent Clostridioides difficile infection, following Phase 2 results showing a greater than 80% reduction in the odds of CDI recurrence versus placebo; VE202 is in development for inflammatory bowel disease and VE707 for prevention of multidrug-resistant organism infections. Vedanta has raised a $68 million Series D and a $106.5 million financing, and its programs are supported by non-dilutive awards from BARDA and CARB-X. Vedanta is a therapeutics developer, not a software vendor: it runs a WordPress marketing and corporate site, publishes no developer portal, no SDKs, no GitHub organization and no machine-readable API contract, and an August 2026 probe of vedantabio.com found no OpenAPI, no /llms.txt, no MCP endpoint, no A2A agent card and an empty /.well-known/ discovery surface.

Vedanta Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Pharmaceuticals, and Microbiome.

Vedanta Biosciences’ developer surface includes support and 27 more developer resources.

🌐 Visit website 📡 Source on GitHub
15.6/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1
0 APIs
CompanyBiotechnologyLife SciencesPharmaceuticalsMicrobiomeLive Biotherapeutic ProductsImmunologyGastroenterologyInfectious DiseaseClinical ResearchDrug DevelopmentHealth CareUnited States

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1
Composite quality — 15.6/100 · emerging
Contract Quality 0.0 / 25
Developer Ergonomics 0.9 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.7 / 13
Governance 1.5 / 12
Discoverability 6.9 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/vedanta-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Vedanta Biosciences Domain Security

TLSv1.3 · DNSSEC · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Conformance
Conformance

Build 2

SDKs, sample code, and the tooling you integrate with

Packages
Packages
 GitHubOrganization
GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact
Contact
 Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService
 PrivacyPolicy
PrivacyPolicy

Company 10

The organization behind the API

Website
Website
 About
About
 Press
Press
 PressRSS
PressRSS
 BlogRSS
BlogRSS
 Partners
Partners
 Careers
Careers
 LinkedIn
LinkedIn
 Twitter
Twitter
 Crunchbase
Crunchbase

Scroll for all 10

Other 9

Properties that don't map to a standard resource type

Leadership
Leadership
 Team
Team
 Pipeline
Pipeline
 Science
Science
 Platform
Platform
 Manufacturing
Manufacturing
 IntellectualProperty
IntellectualProperty
 Publications
Publications
 SecondaryMarket
SecondaryMarket

Scroll for all 9

Source (apis.yml)

apis.yml Raw ↑ 
aid: vedanta-biosciences
name: Vedanta Biosciences
description: 'Vedanta Biosciences is a late clinical-stage biopharmaceutical company headquartered at 19 Blackstone Street
  in Cambridge, Massachusetts, founded by PureTech Health together with a group of scientific co-founders who pioneered the
  modern understanding of cross-talk between the human microbiome and the immune system. The company develops a potential
  new category of oral Live Biotherapeutic Products built from rationally defined consortia of human commensal bacteria grown
  from pure clonal cell banks rather than donor-derived stool, and it maintains technical expertise in the manufacture of
  live organisms. Its lead program, VE303, is an eight-strain defined bacterial consortium in the global Phase 3 RESTORATiVE303
  registrational study for the prevention of recurrent Clostridioides difficile infection, following Phase 2 results showing
  a greater than 80% reduction in the odds of CDI recurrence versus placebo; VE202 is in development for inflammatory bowel
  disease and VE707 for prevention of multidrug-resistant organism infections. Vedanta has raised a $68 million Series D and
  a $106.5 million financing, and its programs are supported by non-dilutive awards from BARDA and CARB-X. Vedanta is a therapeutics
  developer, not a software vendor: it runs a WordPress marketing and corporate site, publishes no developer portal, no SDKs,
  no GitHub organization and no machine-readable API contract, and an August 2026 probe of vedantabio.com found no OpenAPI,
  no /llms.txt, no MCP endpoint, no A2A agent card and an empty /.well-known/ discovery surface.'
url: https://raw.githubusercontent.com/api-evangelist/vedanta-biosciences/refs/heads/main/apis.yml
image: https://www.vedantabio.com/wp-content/uploads/2024/12/vedanta-favicon-300x300.png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Life Sciences
- Pharmaceuticals
- Microbiome
- Live Biotherapeutic Products
- Immunology
- Gastroenterology
- Infectious Disease
- Clinical Research
- Drug Development
- Health Care
- United States
apis: []
x-enrichment:
  date: '2026-08-02'
  status: enriched
  artifacts_added: 5
  pass: local-v1
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/vedanta-biosciences-domain-security.yml
- type: Packages
  url: packages/vedanta-biosciences-packages.yml
- type: Conformance
  url: conformance/vedanta-biosciences-conformance.yml
- type: LLMsTxt
  url: llms/vedanta-biosciences-llms.txt
- type: Website
  url: https://www.vedantabio.com/
- type: About
  url: https://www.vedantabio.com/who-we-are/mission/
- type: Leadership
  url: https://www.vedantabio.com/who-we-are/leadership/
- type: Team
  url: https://www.vedantabio.com/who-we-are/team/
- type: Pipeline
  url: https://www.vedantabio.com/pipeline-programs/pipeline/
- type: Science
  url: https://www.vedantabio.com/our-science/defined-bacterial-consortia/
- type: Platform
  url: https://www.vedantabio.com/our-science/product-engine/
- type: Manufacturing
  url: https://www.vedantabio.com/our-science/manufacturing/
- type: IntellectualProperty
  url: https://www.vedantabio.com/our-science/intellectual-property/
- type: Publications
  url: https://www.vedantabio.com/our-science/publications/
- type: Press
  url: https://www.vedantabio.com/our-science/press-releases/
- type: PressRSS
  url: https://www.vedantabio.com/our-science/press-releases/feed/
- type: BlogRSS
  url: https://www.vedantabio.com/feed/
- type: Partners
  url: https://www.vedantabio.com/who-we-are/partnerships/
- type: Careers
  url: https://www.vedantabio.com/who-we-are/open-positions/
- type: Contact
  url: https://www.vedantabio.com/contact/
- type: Support
  url: https://www.vedantabio.com/contact/
- type: TermsOfService
  url: https://www.vedantabio.com/terms-and-conditions/
- type: PrivacyPolicy
  url: https://www.vedantabio.com/privacy-policy/
- type: GitHubOrganization
  url: https://github.com/vedantabio
- type: LinkedIn
  url: https://www.linkedin.com/company/vedanta-biosciences-inc-
- type: Twitter
  url: https://x.com/vedantabio
- type: Crunchbase
  url: https://www.crunchbase.com/organization/vedanta-biosciences
- type: SecondaryMarket
  url: https://forgeglobal.com/vedanta-biosciences_stock/